Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Why couldn't this be about attempting to distinguish between blood counts dropping due to Gemcitabine, say, vs Necu, or some combination of the two, rather than assuming HIT as the primary mechanism?

What I should have said, to be clearer, is that the incremental thrombocytopenia caused by Necuparanib per se is almost certainly HIT.

To me, "multifactorial" was the key word in the announcement.

Agreed—ascertaining the relative contributions of HIT vs chemo-induced thrombocytopenia is the first order of business. When that’s accomplished, MNTA needs to find a way of addressing HIT in a manner that keeps overall thrombocytopenia at an acceptable level and doesn’t choke enrollment in the trial.